查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1447738

疫苗佐剂市场评估：按产品类型、给药途径、疾病类型、应用和地区划分的机会和预测（2017-2031）

Vaccine Adjuvants Market Assessment, By Product Type, By Route of Administration, Disease Type, By Application, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 223 Pages | 商品交期: 3-5个工作天内

价格

全球疫苗佐剂市场规模预计将从2023年的13.3亿美元成长到2031年的28.4亿美元，2024-2031年预测期内复合年增长率为9.95%，预计规模也将持续扩大。

由于几个关键因素，全球疫苗佐剂市场正在经历显着成长。 传染病的爆发导致疫苗需求增加，支持市场扩张。 生物技术的技术进步也在推动市场发展方面发挥着重要作用。 此外，政府对研发活动的资助和投资的增加也推动了这一成长轨迹。 主要参与者之间的策略联盟和合作也是促进市场拓展的重要因素。

对疫苗、生物製药和治疗药物的需求不断增加

比以往任何时候都需要更多的疫苗、生物製药和治疗方法。 COVID-19 让疫苗在现在和未来变得更加重要。 疫苗佐剂是疫苗的重要组成部分，随着疫苗使用量的增加，对疫苗佐剂的需求也会增加。 在医疗领域，生物製药、基因治疗药物、细胞治疗药物越来越受欢迎。 人口成长、疾病传播、大流行威胁、新冠疫情后的应对措施以及公众意识的提高等因素将推动未来几年对疫苗佐剂的需求。

传染病疫情蔓延

由于气候变迁、快速都市化和土地利用模式变化等多种因素，传染病的流行正在增加。 这些因素导致新疾病的出现、旧疾病的重新出现以及现有疾病的传播。 技术变革，例如医疗保健的改善和全球旅行，也会导致传染病的传播。 此外，人口成长和移民等人口变化也会增加疾病爆发的风险。 随着传染病流行的增加，对疫苗的需求也增加。 世界卫生组织（WHO）估计，全球每年约三分之一的死亡是由传染病造成的，其中急性呼吸道感染、胃肠道感染、结核病和疟疾是全球主要疾病，造成大部分死亡。

碳水化合物佐剂成长迅速

以碳水化合物为基础的佐剂在疫苗开发中越来越受欢迎。 它们被认为是安全的并且与身体相容，并且可以诱导和控制免疫反应。 这些佐剂与次单位疫苗搭配使用，可以帮助增强人体的免疫反应，使疫苗更有效。 天然和合成碳水化合物已在临床试验中作为佐剂进行了测试，其中一些已被批准用于人类疫苗。 碳水化合物佐剂具有多种优点，包括与身体更好的相容性、更好的耐受性和更高的安全性。 从这些角度来看，它被认为是一种有前途的疫苗佐剂。

本报告调查了全球疫苗佐剂市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素分析、案例研究、竞争格局、主要公司的简介等等。

目录

第1章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第4章全球疫苗佐剂市场展望

  • 市场规模/预测
  • 依产品类型
    • 矿物盐佐剂
    • 张力活性佐剂
    • 佐剂乳液
    • 脂质体佐剂
    • 碳水化合物佐剂
    • 细菌佐剂
    • 病毒样颗粒 (VLP)
    • 其他
  • 依给药途径
    • 皮下
    • 肌肉注射
  • 依疾病类型
    • 传染病
    • 癌症
  • 依用途
    • 研究
    • 商业
  • 按地区
    • 北美
    • 欧洲
    • 南美洲
    • 亚太地区
    • 中东/非洲
  • 各公司的市占率

第5章全球疫苗佐剂市场前景：依地区划分

  • 北美
  • 欧洲
  • 南美洲
  • 亚太地区
  • 中东/非洲

第 6 章市场映射

  • 依产品类型
  • 依给药途径
  • 依疾病类型
  • 依用途
  • 按地区

第7章宏观环境/产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 抑制生长的因素（问题/抑制因素）

第 9 章监理架构与创新

  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第10章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（主要公司）

第11章价格分析

第 12 章案例研究

第13章主要公司展望

  • Brenntag Biosector A/S
  • OZ Biosciences.
  • Agenus, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • SEPPIC, Inc.
  • Novavax, Inc.
  • MPV Technologies
  • CSL Corporate
  • Avanti Polar Lipids, Inc.
  • Invivogen

第 14 章策略建议

第15章关于我们公司/免责声明

Product Code: MX11145

Global vaccine adjuvants market is projected to witness a CAGR of 9.95% during the forecast period 2024-2031F, growing from USD 1.33 billion in 2023 to USD 2.84 billion in 2031. The global vaccine adjuvants market is witnessing substantial growth driven by several key factors. The increasing prevalence of infectious diseases has led to a rising demand for vaccines, propelling market expansion. Technological advancements in biotechnology are also playing a significant role in driving the market forward. Moreover, increased government funding and investments in research and development activities are fueling this growth trajectory. Strategic collaborations and partnerships among key industry players are also acting as crucial factors contributing to the market's expansion. Vaccine adjuvants enhance immunogenicity, leading to more effective vaccines with reduced antigen content, crucial for mass vaccination campaigns. However, challenges like side effects and toxicity associated with some adjuvants, particularly aluminum adjuvants, which can cause local injection site reactions and allergic responses hinder the market. Additionally, the concern for public health and safety may limit the adoption of certain adjuvants if they pose risks or potential harm to individuals receiving them.

In October 2023, after careful evaluation, the World Health Organization (WHO) approved the use of the R21/Matrix-M malaria vaccine. Developed by the University of Oxford, the Serum Institute of India, and leveraging Novavax's adjuvant technology, the vaccine has met strict standards for safety, quality, and effectiveness. Experts from the WHO's independent advisory groups, SAGE and MPAG, conducted a thorough review and found that the vaccine is effective and safe. Clinical trials in various regions with different malaria transmission rates have demonstrated its efficacy.

Growing Demand for Vaccines, Biopharmaceuticals, and Therapy Products

More vaccines, biopharmaceuticals, and therapies are needed than ever before. COVID-19 has made vaccines even more essential, both now and in the future. Vaccine adjuvants are essential components of vaccines and increasing the use of vaccines will ultimately enhance the demand for vaccine adjuvants. In the medical sector, biopharmaceuticals, gene therapies, and cell therapies are becoming more and more popular. Factors, such as population growth, escalating disease prevalence, pandemic threats, post-COVID readiness measures, and heightened public awareness, are driving the demand for vaccine adjuvants in the upcoming years.

As per the WHO report published in May 2023, between the years 2019 and 2021, a significant increase in the consumption of vaccines has been observed. The adult vaccines segment grew by 15%, pediatric vaccines registered a growth of 8%, and vaccines used for adolescents registered a growth of 7%. This data does not consider COVID-19 vaccines, but still, a significant change in demand can be seen.

Growing Prevalence of Infectious Diseases

The prevalence of infectious diseases is increasing due to several factors, including climate change, rapid urbanization, and changes in land-use patterns. These factors contribute to the emergence of new diseases, the re-emergence of old diseases, and the spread of existing diseases. Technological changes, such as improved health care and global travel, also contribute to the spread of infectious diseases. Additionally, demographic changes, such as population growth and migration, can increase the risk of disease emergence. As the prevalence of infectious diseases increases, the demand for vaccines rises, subsequently enhancing the market demand for vaccine adjuvants as they are essential components of the finished vaccines. The World Health Organization estimates that approximately one-third of annual deaths worldwide are attributed to infectious diseases, with acute respiratory tract infections, gastrointestinal infections, tuberculosis, and malaria causing most of the illnesses and mortality worldwide.

For instance, as per the data published by Worldometers, over 703 million COVID-19 cases were reported till February 2024, along with 69 million deaths reported. COVID-19 has been the most contagious and lethal infectious disease in recent times.

Carbohydrate-based Adjuvants are Fastest Growing

Carbohydrate-based adjuvants are becoming increasingly popular in vaccine development. They are considered safe and compatible with the body, and they can trigger and control immune responses. These adjuvants help make vaccines more effective by boosting the body's immune response when used with subunit vaccines. Natural and synthetic carbohydrates have been tested as adjuvants in clinical trials, and some have been approved for use in human vaccines. Carbohydrate-based adjuvants offer several advantages, including being highly compatible with the body, well-tolerated, and having a good safety record. These factors make them promising candidates for use as adjuvants in vaccines.

Infectious Disease to be the Leading Disease Type

The infectious disease segment is expected to be the leading disease type for utilizing vaccines for treatment purposes. A variety of vaccines are available in the market for infectious diseases like hepatitis, polio, tetanus, and influenza. Vaccines are highly effective in infectious diseases because they provide long-lasting immunity, protect against severe illness and death, and reduce the spread of the disease within a population. Vaccines work by imitating an infection, engaging the body's natural immune response, and providing protection without the dangers of a full-blown infection. Vaccines are more effective in infectious diseases because they target specific pathogens, and their development is based on the characteristics of the pathogen, such as antigenic stability, serotype, and the presence of diagnostic tests or clinical criteria for measuring disease burden.

In May 2023, GSK announced the US Food and Drug Administration's approval for its Arexvy (respiratory syncytial virus vaccine, adjuvanted) meant for the prevention of lower respiratory tract disease (LRTD) caused due to respiratory syncytial virus (RSV) in patients of 60 years of age and older. Arexvy is the world's first RSV vaccine for elders to be approved.

North America to be the Dominating Region

North America's leadership in the vaccine adjuvant market stems from several key reasons. Governments are investing heavily in research, and companies within the industry are partnering to achieve breakthroughs. The region's healthcare system is well-developed, with a focus on preventive care. This encourages the use of adjuvanted vaccines, which make vaccines more effective and are thoroughly tested before being approved. This reflects the region's commitment to preventive healthcare measures. Additionally, the region's strong regulatory framework ensures the safety and efficacy of adjuvanted vaccines, further boosting market confidence. US FDA considers vaccine adjuvant as a part of the vaccine and not as a separate entity, thus separate approval for vaccine adjuvant is not required.

Future Market Scenario

The future of vaccine adjuvants is expected to focus on the development of new, more effective, and safer adjuvants. Research is being conducted to create adjuvants that can enhance the immune response to vaccines, particularly for subunit vaccines, which are often less effective at generating a robust immune response. New adjuvants are being developed from natural resources and synthetic components, to improve safety and protective efficacy. Technologies, such as nanotechnologies and molecular biology, are being used to improve vaccine efficacy, and adjuvants are being designed to stimulate immune responses in a more targeted manner. Additionally, systems vaccinology approaches are being used to assess and characterize new adjuvant systems, which may help in the rational design of vaccines in the future.

Key Players Landscape and Outlook

Brenntag Biosector A/S, OZ Biosciences, Agenus, Inc., Spectrum Pharmaceuticals, Inc., SEPPIC, Inc., Novavax, Inc., and MPV Technologies are some of the key players in the vaccine adjuvants market. These companies are actively involved in the production and advancement of vaccine adjuvants, contributing to the growth and innovation within the industry. The market is competitive, with a focus on enhancing vaccine efficacy, reducing production costs, and developing safer and more effective vaccines through ongoing advancements in technology and formulations.

In February 2024, DTRA's JSTO awarded a USD 31 million, 5-year contract to Ginkgo Bioworks and SaponiQx through the MCDC program to develop cutting-edge vaccine adjuvants. Ginkgo, specializing in cell programming and biosecurity, and SaponiQx, with its innovative adjuvant platform, have been collaborating on this project since 2021.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Vaccine Adjuvants Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2.By Product Type
    • 4.2.1.Mineral Salt-based Adjuvant
    • 4.2.2.Tensoactive Adjuvants
    • 4.2.3.Adjuvant Emulsions
    • 4.2.4.Liposome Adjuvants
    • 4.2.5.Carbohydrate Adjuvants
    • 4.2.6.Bacteria-derived Adjuvants
    • 4.2.7.Virus-like Particles (VLP)
    • 4.2.8.Others
  • 4.3.By Route of Administration
    • 4.3.1.Subcutaneous
    • 4.3.2.Intramuscular
  • 4.4.Disease Type
    • 4.4.1.Infectious Diseases
    • 4.4.2.Cancer
  • 4.5.By Application
    • 4.5.1.Research Applications
    • 4.5.2.Commercial Applications
  • 4.6.By Region
    • 4.6.1.North America
    • 4.6.2.Europe
    • 4.6.3.Asia-Pacific
    • 4.6.4.South America
    • 4.6.5.Middle East and Africa
  • 4.7.By Company Market Share (%), 2023

5.Global Vaccine Adjuvants Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Product Type
      • 5.1.2.1.Mineral Salt-based Adjuvant
      • 5.1.2.2.Tensoactive Adjuvants
      • 5.1.2.3.Adjuvant Emulsions
      • 5.1.2.4.Liposome Adjuvants
      • 5.1.2.5.Carbohydrate Adjuvants
      • 5.1.2.6.Bacteria-derived Adjuvants
      • 5.1.2.7.Virus-like Particles (VLP)
      • 5.1.2.8.Others
    • 5.1.3.By Route of Administration
      • 5.1.3.1.Subcutaneous
      • 5.1.3.2.Intramuscular
    • 5.1.4.Disease Type
      • 5.1.4.1.Infectious Diseases
      • 5.1.4.2.Cancer
    • 5.1.5.By Application
      • 5.1.5.1.Research Applications
      • 5.1.5.2.Commercial Applications
    • 5.1.6.United States*
      • 5.1.6.1.Market Size & Forecast
      • 5.1.6.1.1.By Value
      • 5.1.6.1.2.By Volume
      • 5.1.6.2.By Product Type
      • 5.1.6.2.1.Mineral Salt-based Adjuvant
      • 5.1.6.2.2.Tensoactive Adjuvants
      • 5.1.6.2.3.Adjuvant Emulsions
      • 5.1.6.2.4.Liposome Adjuvants
      • 5.1.6.2.5.Carbohydrate Adjuvants
      • 5.1.6.2.6.Bacteria-derived Adjuvants
      • 5.1.6.2.7.Virus-like Particles (VLP)
      • 5.1.6.2.8.Others
      • 5.1.6.3.By Route of Administration
      • 5.1.6.3.1.Subcutaneous
      • 5.1.6.3.2.Intramuscular
      • 5.1.6.4.Disease Type
      • 5.1.6.4.1.Infectious Diseases
      • 5.1.6.4.2.Cancer
      • 5.1.6.5.By Application
      • 5.1.6.5.1.Research Applications
      • 5.1.6.5.2.Commercial Applications
    • 5.1.7.Canada
    • 5.1.8.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Product Type
  • 6.2.By Route of Administration
  • 6.3.By Disease Type
  • 6.4.By Application
  • 6.5.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.4.7.Supplier Power
    • 7.4.8.Buyer Power
    • 7.4.9.Substitution Threat
    • 7.4.10.Threat from New Entrant
    • 7.4.11.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Patent Landscape
  • 9.2.Regulatory Approvals
  • 9.3.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Brenntag Biosector A/S
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.OZ Biosciences.
  • 13.3.Agenus, Inc.
  • 13.4.Spectrum Pharmaceuticals, Inc.
  • 13.5.SEPPIC, Inc.
  • 13.6.Novavax, Inc.
  • 13.7.MPV Technologies
  • 13.8.CSL Corporate
  • 13.9.Avanti Polar Lipids, Inc.
  • 13.10.Invivogen

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 3.Global Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 4.Global Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5.Global Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 6.Global Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 7.Global Vaccine Adjuvants Market Share (%), By Region, 2017-2031F
  • Figure 8.North America Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 9.North America Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 10.North America Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 11.North America Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 12.North America Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 13.North America Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 14.North America Vaccine Adjuvants Market Share (%), By Country, 2017-2031F
  • Figure 15.United States Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 16.United States Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 17.United States Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 18.United States Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 19.United States Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 20.United States Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 21.Canada Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 22.Canada Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 23.Canada Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 24.Canada Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 25.Canada Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 26.Canada Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 27.Mexico Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 28.Mexico Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 29.Mexico Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 30.Mexico Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 31.Mexico Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 32.Mexico Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 33.Europe Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 34.Europe Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 35.Europe Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 36.Europe Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 37.Europe Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 38.Europe Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 39.Europe Vaccine Adjuvants Market Share (%), By Country, 2017-2031F
  • Figure 40.Germany Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 41.Germany Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 42.Germany Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 43.Germany Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 44.Germany Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 45.Germany Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 46.France Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.France Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 48.France Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 49.France Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 50.France Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 51.France Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 52.Italy Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 53.Italy Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 54.Italy Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 55.Italy Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 56.Italy Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 57.Italy Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 58.United Kingdom Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 59.United Kingdom Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 60.United Kingdom Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 61.United Kingdom Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 62.United Kingdom Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 63.United Kingdom Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 64.Russia Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 65.Russia Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 66.Russia Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 67.Russia Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68.Russia Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 69.Russia Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 70.Netherlands Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 71.Netherlands Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 72.Netherlands Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 73.Netherlands Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 74.Netherlands Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 75.Netherlands Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 76.Spain Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 77.Spain Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 78.Spain Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 79.Spain Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 80.Spain Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 81.Spain Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 82.Turkey Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 83.Turkey Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 84.Turkey Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 85.Turkey Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 86.Turkey Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 87.Turkey Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 88.Poland Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Poland Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 90.Poland Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 91.Poland Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 92.Poland Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 93.Poland Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 94.South America Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 95.South America Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 96.South America Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 97.South America Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 98.South America Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 99.South America Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 100.South America Vaccine Adjuvants Market Share (%), By Country, 2017-2031F
  • Figure 101.Brazil Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 102.Brazil Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 103.Brazil Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 104.Brazil Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105.Brazil Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 106.Brazil Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 107.Argentina Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 108.Argentina Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 109.Argentina Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 110.Argentina Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 111.Argentina Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 112.Argentina Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 113.Asia-Pacific Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 114.Asia-Pacific Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 115.Asia-Pacific Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 116.Asia-Pacific Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 117.Asia-Pacific Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 118.Asia-Pacific Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 119.Asia-Pacific Vaccine Adjuvants Market Share (%), By Country, 2017-2031F
  • Figure 120.India Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 121.India Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 122.India Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 123.India Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 124.India Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 125.India Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 126.China Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 127.China Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 128.China Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 129.China Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130.China Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 131.China Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 132.Japan Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 133.Japan Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 134.Japan Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 135.Japan Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 136.Japan Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 137.Japan Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 138.Australia Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 139.Australia Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 140.Australia Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 141.Australia Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 142.Australia Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 143.Australia Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 144.Vietnam Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 145.Vietnam Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 146.Vietnam Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 147.Vietnam Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 148.Vietnam Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 149.Vietnam Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 150.South Korea Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 151.South Korea Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 152.South Korea Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 153.South Korea Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 154.South Korea Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 155.South Korea Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 156.Indonesia Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 157.Indonesia Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 158.Indonesia Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 159.Indonesia Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 160.Indonesia Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 161.Indonesia Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 162.Philippines Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 163.Philippines Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 164.Philippines Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 165.Philippines Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 166.Philippines Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 167.Philippines Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 168.Middle East & Africa Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 169.Middle East & Africa Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 170.Middle East & Africa Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 171.Middle East & Africa Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 172.Middle East & Africa Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 173.Middle East & Africa Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 174.Middle East & Africa Vaccine Adjuvants Market Share (%), By Country, 2017-2031F
  • Figure 175.Saudi Arabia Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 176.Saudi Arabia Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 177.Saudi Arabia Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 178.Saudi Arabia Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 179.Saudi Arabia Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 180.Saudi Arabia Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 181.UAE Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.UAE Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 183.UAE Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 184.UAE Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 185.UAE Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 186.UAE Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 187.South Africa Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
  • Figure 188.South Africa Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
  • Figure 189.South Africa Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
  • Figure 190.South Africa Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
  • Figure 191.South Africa Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
  • Figure 192.South Africa Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
  • Figure 193.By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195.By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196.By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023